Compare Moderna, Inc. (MRNA) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while YieldMax NVDA Option Income Strategy ETF trades at $12.57 (market cap $1.45B). The key difference: Moderna, Inc. is far larger — about 54.2× YieldMax NVDA Option Income Strategy ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| MRNA | NVDY | |
|---|---|---|
Market Cap | $78.65B | $1.45B |
Volume | 37,373,437 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $203.46 | $17.21 |
52-Week Low | $22.36 | $11.58 |
Typical Hold Time | 59 Days | 43 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.62, down 3.0% today amid bearish technical signals. The ETF generates income through covered calls on NVIDIA stock but faces structural limitations on upside participation. Recent analyst commentary highlights concerns about NAV erosion despite the attractive 39.7% annualized distribution rate. Technical indicators show bearish momentum with support at $12 and resistance at $13.
The outlook remains cautious as declining NVIDIA volatility reduces option income potential. While weekly distributions provide income, the capped upside and NAV erosion present significant risks for long-term investors. Analyst consensus leans toward Hold ratings, suggesting limited growth prospects despite strong underlying NVIDIA fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
